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1. INTRODUCTION 
1.1 TABLETS: 
This chapter deals first with the main aspects of tablet dosage forms before addressing the 
process of manufacture and testing of these most popular drug delivery systems. Per oral tablets 
occupy the broadest and the most significant place among all pharmaceutical dosage forms. 
Taking one or two tablets a day with a glass of water is the easiest and the most acceptable way 
of administration of a drug to a patient. William Brockedon patented the first tablet press in 1843 
to compress potash and lime tablets, thus paving the way for the modern manufacture of tablets. 
Drugs are administered in a wide variety of doses. Tablets of L-thyroxine, for example, may 
contain as low as 25 mg drug. On the other hand, amoxicillin/clavulanicacid tablets contain 1 g 
of actives per tablet. These two extremes cover a 10,000-fold range of drug content. Tablets may 
be made in different sizes and shapes, and the drug substance may comprise 0.1% to 90% of a 
tablet bulk. From the point of view of ease of manufacture, tablet production, compared with 
other dosage forms, provides the highest output per manufacturing hour, and is the most 
economical, especially if one considers modern manufacturing methods involving processes 
suchas the direct compression (DC) or fluidized-bed granulation. While tabletting may appear 
from what has been said to be a facile process, it is often far from straightforward. Drug 
molecules show various differences in physical and chemical properties. These include 
differences in their crystalline structure, particle size, water solubility, dose, and sensitivity to 
hydrolysis or oxidation, topics discussed elsewhere in this book. Hence, every drug molecule 
must be treated as a unique entity for formulation. Drugs synthesized in the last 30 years have 
been increasingly showing limited water solubility, poor flow and compression properties, and 
sensitivity to moisture and heat. Preparing a tablet dosage form from such molecules is a 
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challenge, since the market demands easy and cost-effective manufacturing, an acceptable 
dissolution rate, and of course high bioavailability, and mechanically strong tablets that resist 
fracture during packaging, 
Transport and ultimately in patient use. Further more, the tablets must fulfill the requirements for 
bioavailability and, eventually, bioequivalence. When considering all these factors, designing 
and manufacturing a successful tablet requires optimization of the formulation and processing 
parameters, which can be achieved by the application of a thorough knowledge of excipients, and 
the subsequent selection of the most suitable manufacturing process.[1] 
 
1.1 a) ADVANTAGES OF TABLETS: 
9 Tablets are the unit dosage form having greatest capabilities of all oral dosage form for 
the dose precision and least content variability. 
9 Their cost is lower of all oral dosage forms. 
9 They are lightest and the most compact of all oral dosage forms. 
9 Tablets are easiest and cheapest for packaging and transportation. 
9 They lend themselves to certain special release profile products such as enteric or delayed 
release products. 
9 Tablets are better for large -scale production than other unit oral forms. 
9 They have the best-combined properties of chemical, mechanical, microbiological 
stability of all oral forms. 
9 Tablets are easiest and cheapest for packaging and transportation.[2] 
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1.1 b) LIMITATIONS OF THE TABLETS: 
9 Some drugs resist compression in to dense particles, owing to their amorphous nature or 
flocculent, low-density character. 
9 Drugs with poor wetting slow dissolution properties, intermediate to large dosages, 
optimum absorption high in the GIT, or any combination of these features difficult to 
formulate. 
9 Bitter tasting drugs with an objectionable odor, or drugs that are sensitive to oxygen or 
atmospheric moisture may require encapsulation or entrapment prior to compression. 
 
1.2 TYPES OF TABLETS AND TABLET DESIGN: 
Tablet design is based on the experience and knowledge of excipients, which are 
materials serving the purpose of making a good tablet when combined with a drug. The 
mechanical and chemical properties of excipients have the utmost importance, and the area is 
closely related to materials engineering as well as pharmacy. Expected properties of a modern 
tablet include mechanical strength suitable for coating, packaging, and transportation; an 
optimum size, shape, and color for identification; ease of swallowing; and, finally, fulfilling the 
pharmacopoeial requirements for drug content and release rates as well as stability and 
bioavailability. Some of the pharmaceutical tablet types based on the way of administration or 
presentation to the patient are listed below: 
¾ Simple uncoated tablets 
¾ Coated tablets 
¾ Effervescent tablets 
¾ Buccal and sublingual tablets 
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¾ Chewable tablets 
¾ Multilayered tablets 
¾ Sugarcoated tablets 
¾ Fast-disintegrating tablets 
¾ Vaginal tablets 
¾ Modified release tablets 
¾ Extended release tablets 
 
 a) Simple Uncoated Tablets 
The simplest form of a pharmaceutical tablet consists of a combination of a drug and some 
functional excipients compressed directly. This tablet should be formed by compression without 
difficulty using binders, disintegrants, and lubricants, and when used by a patient, it should 
disintegrate in the stomach and should of course be bioavailable. Such simple tablets are 
manufactured by mixing the drug and excipients in a V-shaped mixer and are compressed in a 
tablet press using dies and punches of suitable size. 
 
 b) Film-Coated Tablets 
A tablet can be coated with a polymer film to provide greater ease of swallowing, protection 
against light or moisture, protection of the drug from gastric acidity, and modification or control 
of drug release rate. Identification of a formulation by color or logo is extremely important today 
not only for patient safety but also because of the problem of counterfeiting. Polymers and 
processes are available to achieve all of these properties. 
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 c) Effervescent Tablets 
Effervescent tablets are designed to dissolve or disperse quickly in water as a result of the release 
of carbon dioxide from the reaction between sodium bicarbonate and citric acid in the 
formulation. Such tablets are generally the largest tablets in terms of size and weight, with 
diameters up to 3 cm and weights of the order of 4 to 5 g. Although they are called tablets, the 
mode of administration is naturally indirect; the patients take the drug solution or suspension 
after dispersal. Their manufacture may require a low humidity environment, special tablet 
presses, and specialized lubrication for tablet ejection. 
 
 d) Buccal and Sublingual Tablets 
These special tablets are designed for fast and complete drug action through dissolution in the 
buccal cavity or placement sublingually. As a result, the first pass effect may be avoided. Buccal 
tablets are used for hormone replacement therapy, for example, with methyl testosterone; 
sublingual tablets are frequently used for the delivery of isosorbidedinitrate and nitroglycerin.  
 
 e) Chewable Tablets 
Sometimes a tablet is designed in such a way that it is chewable. This results in its disintegration. 
Chewable tablets have some advantages, among them being that a large dose of a drug can be 
formulated, since the tablets are not swallowed whole. Children can be convinced to take such 
medication, no water is required for administration, and the disintegration step for a tablet is 
actively achieved in the mouth before it dissolves in the gastric medium. Pediatric multivitamin 
or mineral formulas, aspirin, vitamin C 1000 mg,and vitamin A 50,000 units are usually 
formulated as chewable tablets. 
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            f) Multilayered Tablets 
Tablets can be designed and manufactured to have separate layers or a core tablet inside a tablet. 
In this way, two or more drugs can be kept separate in a single tablet. Such complicated systems 
have found limited applications over the years in the pharmaceutical industry, but there is a 
revival of interest in the use of combination dosage forms for thetreatment of diseases such as 
AIDS, where multiple drugs are administered each day. Tablet presses with two or three hoppers 
are available for the purpose of preparing multilayered dose forms. These include the Colton 
232, the KilianPrescoter, and the ManestyDryCota machines. Recently, an excellent application 
potential was reported for compression coating, namely, the colonic delivery of drugs using a 
pectin-hydroxypropyl methyl cellulose (HPMC) combination, which was successful for the 
delivery of 5-aminosalycylic acid (5-ASA), and also for peptides such as nisin. This type of drug 
delivery system requires compression-coating equipment for mass production since a 100- mg 
core tablet containing the drug is surrounded by a pectin-HPMC mixture. 
 
              g) Sugarcoated Tablets (Dragees) 
Before the development of film-coating processes, the major coating material was a sugarcoat. 
Tablets were sugarcoated for the very same reasons as film coating. These tablet types generally 
start with a seed or core tablet that contains the drug, and the resultant coating process is a 
lengthy one using simple syrup, shellac, and talc, several layers of which are deposited onto the 
core tablet. Usually, a weight increase of as muchas 100% to 300% is considered normal. 
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h) Fast-Disintegrating Tablets 
This type of tablet is the newest addition to the family of tablets. The main reason for the 
development of such tablets is the potential for administration of small doses to the elderly or 
children who have difficulties in swallowing intact tablets. A tablet is administered by placing it 
on a spoon and adding some water, in two to four seconds the tablet completely disintegrates to 
granules that can be swallowed easily. Fast-disintegrating tablets are not only made out of 
special granules but can also be compressed using coated spherical pellets such as enteric-coated 
omeprazole pellets. 
 
i) Vaginal Tablets 
Tablets are made to be used for insertion into the vagina for treatment of local infections or 
hormone replacement therapy. For instance, ornidazole and micanazole nitrate combination and 
estradiol hemihydrate tablets are formulated as vaginal tablets. These tablets release the drugs 
slowly in 20 to 30 minutes. 
 
 j) Modified-release tablets:  
In order to overcome the drawbacks of conventional drug delivery systems, several technical 
advancements have led to the development of modified release drug delivery systems. The 
modified-release delivery systems may be divided conveniently into four categories:  
1. Delayed release  
2. Sustained release  
3. Site-specific targeting  
4. Receptor targeting  
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i) Delayed release system: Delayed-release systems are those that use repetitive, 
intermittent dosing of a drug from one or more immediate-release units incorporated into a single 
dosage form. Examples of delayed-release systems include repeat-action tablets and capsules, 
and enteric-coated tablets where timed release is achieved by a barrier coating.  
 
ii) Sustained release system: During the past few years, conventional dosage forms of 
drugs are rapidly being replaced by the new and the novel drug delivery systems. Amongst, these 
the controlled release/sustained release dosage forms have become extremely popular in modern 
therapeutics. The basic rationale for sustained release drug delivery is to alter the 
pharmacokinetics and pharmacodynamics of drugs by using novel drug delivery systems or by 
modifying the molecular structure or physiological parameters inherent in a selected route of 
administration. It is desirable that the duration of drug action becomes more a design property of 
a rate controlled dosage form and less or not at all a property of the drug molecule’s inherent 
kinetic properties. Thus, optimal design of a sustained/ controlled release system necessitates a 
thorough understanding of the pharmacokinetics and pharmacodynamics of the drug. When the 
drug is administered in a conventional dosage form, it results in a fluctuation of drug 
concentration at the site of action (peak and valley pattern) and therefore in systemic circulation 
and tissue compartment. 
¾ Advantages of sustained release drug delivery:  
Following are the potential advantages of sustained release products  
• Decreased local and systemic side effects reduced gastrointestinal irritation.  
• Better drug utilization reduction in total amount of drug used.  
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• Improved efficiency in treatment, optimized therapy, more uniform blood 
concentration.  
• Reduction in fluctuation in drug level and hence more uniform pharmacological 
response, cure of control of condition more promptly, less reduction in drug 
activity with chronic use.  
• Method by which sustained release is achieved can improve the bioavailability of 
some drugs e.g. drugs susceptible to enzymatic inactivation can be protected by 
encapsulation in polymer systems suitable for sustained release.  
• Improved patient compliance, less frequent dosing, reduced night-time dosing, 
reduced patient care time. The importance of patient compliance in successful 
drug therapy is well recognized. It has been found that there is an inverse 
relationship between the number of dosages per day and the compliance rate.  
• Although the initial unit cost of sustained release products is usually greater than 
that of conventional dosage forms because of the special nature of these products, 
the average cost of treatment over an extended time period may be less. Economy 
may also result from a decrease in nursing time and hospitalization time.  
¾ Disadvantages of sustained release drug delivery:  
The disadvantages of sustained release drug delivery system are  
• Decreased systemic availability in comparison to immediate release conventional 
dosage forms, which may be due to incomplete release, increased first-pass 
metabolism, increased instability, insufficient residence time complete release, 
site specific absorption, pH dependent stability, etc.  
• Poor in vitro – in vivo correlation.  
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• Retrieval of drug is difficult in case of toxicity, poisoning or hypersensitivity 
reactions.  
• Reduced potential for dose adjustment of drugs normally administered in varying 
strengths. 
 
iii) Site-specific targeting: Site-specific and receptor targeting refer to targeting of a 
drug directly to a certain biological location. In the case of site-specific release, the target is 
adjacent to or in the diseased organ or tissue.  
 
iv) Receptor targeting: For receptor release, the target is the particular receptor for a 
drug within an organ or tissue. Both of these systems satisfy the spatial aspect of drug delivery 
and are also considered to be controlled drug-delivery systems.[4]  
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   Figure: 2 Controlled release dosage form 
1.3.1 ADVANTAGES OF ORAL EXTENDED RELEASE DELIVERY SYSTEM 
¾ Reduce amount of drug administration 
¾ Maximizing availability with minimum dose 
¾ Causes less fluctuation of plasma drug level 
¾ Leads to more uniform drug effect and lesser total dose.  
¾ Improved patient compliance, resulting from the reduction in the number and frequency 
of doses required to maintain the desired therapeutic response 
¾ There is a reduction in the incidence and severity of localized gastrointestinal side-effects 
produced by 'dose dumping' of irritant drugs from conventional dosage forms, e.g. 
potassium chloride. The more controlled, slower release of potassium chloride from it’s 
per oral ER formulations minimizes the build-up of localized irritant concentrations in the 
gastrointestinal tract. Consequently, potassium chloride is now administered per orally 
almost exclusively in ER form. 
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1.3.2 DISADVANTAGES OF ORAL EXTENDED RELEASE DELIVERY SYSTEM 
¾ Generally higher cost, 
¾ Relatively poor in vitro/in vivo correlation,  
¾ Unpredictable and even reduced bioavailability and subjected to increased first pass 
metabolism for certain drugs. [8] 
 
1.4 TABLET FORMULATION DESIGN: 
Tablet formulation design starts with a predetermined value, which is the dose size. The 
amount of drug in a tablet can be a limiting step in formulation design. Tablet excipients can be 
classified on the basis of their functionality as listed below: 
Fillers/diluents 
Binders 
Disintegrants 
Lubricants 
Glidants 
Buffering agents 
Sweeteners 
Wetting agents 
Coating agents 
Matrix formers 
1.4.1 Fillers/diluents used in tablet formulations 
¾ Lactose (a-lactose monohydrate, anhydrite b-lactose, spray-dried lactose) 
¾ Microcrystalline cellulose (Avicel PH 101, Avicel PH 200, Emcocel) 
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¾ Starch (Corn starch, partially hydrolyzed starch) 
¾ Dibasic calcium phosphate (Emcompress, Di-Tab) 
¾ Mannitol (Parteck, Delta M) 
¾ Sorbitol (Neosorb 60) 
¾ Calcium sulfate (Delaflo) 
¾ Compressible sucrose (Di-Pac, Des-tab, Nu-Tab) 
 
1.4.2 Binders used in tablet formulations 
¾ Polyvinylpyrrolidone (PVP) 
¾ Sodium carboxymethyl cellulose 
¾ HPMC (Low molecular weight, 5 cps) 
¾ Starch paste 
¾ Simple syrup 
 
1.4.3 Lubricants and glidants used in tablet formulations 
¾ Magnesium stearate 
¾ Stearic acid 
¾ Sodium stearylfumarate 
¾ Hydrogenated vegetable oil 
¾ PEG 4000, 6000 
¾ Hexagonal boron nitride 
¾ DL-Leucine 
¾ Sodium lauryl sulfate 
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¾ Glicerylbehenate 
¾ Sodium benzoate 
¾ Colloidal silicone dioxide 
¾ Talc 
¾ Starch 
 
1.4.4 Super disintegrants 
¾ Sodium starch glycolate (Explotab) 
¾ Cross-linked PVP (Polyplasdone XL) 
¾ Cross-linked carboxymethyl cellulose (Ac-Di-Sol) 
 
1.4.5 Coprocessed Excipient Products 
Some flexibility is necessary in the design of tablet formulations. Selecting each 
excipient depends on the physical and chemical properties of the drug, the drug dose, and the 
required final form and function of the tablet. There are however aids for the formulator. There 
are some coprocessed excipients containing usually a diluent and binder, and sometimes, even a 
disintegrant in a readymade granulation. LudipressTM(BASF, Germany) contains a-lactose 
monohydrate, polyvinylpyrrolidone (PVP), and KollidonCL. Cellactose 80TM (Meggle, 
Germany) contains a-lactose monohydrate and cellulose powder, ProsolvTM SMCC (JRS 
Pharma, Germany), silicified MCC, contains 98% MCC and 2% colloidal silicon dioxide, which 
provides a better granule flow and an opportunity for smaller and denser tablets upon direct 
compression. There are also coprocessed actives like ascorbic acid, thiamine, riboflavine, 
pyridoxine, paracetamol and acetyl salicylicacid. For those drugs that are manufactured in huge 
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volumes, the use of coprocessed excipients is efficient, since the small capacity of many 
pharmaceutical manufacturing plants for wet or dry granulation cannot deal with huge volumes. 
Materials that contribute to plastic deformation, which means stronger compacts upon 
compression or forming a matrix such as methyl cellulose (MC), HPMC, hydoxypropyl cellulose 
(HPC), cellulose powder, gelatine and mannitol are used. Coprocessed products are so designed 
that by simple addition of the drug, compressed tablets may be produced. Using coprocessed 
active allows minimum excipient addition and manipulation. 
 
1.4.6 Fillers/Diluents 
Fillers are used to arrive at a tablet of reasonable size when a drug forms a small portion 
of the formula, as in the case of 25 mg estradiol vaginal tablets. Depending on the physiological 
conditions and formulation, one needs a tablet of around 100 mg for ease of handling and 
administration, and therefore, fillers are used to increase bulk. Usually, a-lactose monohydrate is 
the first material to be considered. This water soluble disaccharide is obtained from whey by 
crystallization and drying after cheese production. Lactose is a water-soluble diluent, 216 mg 
dissolving in 1-mL water. Using three different drying techniques, fluidized-bed methods, roller 
drying, and spray drying, a-lactose monohydrate, anhydrous b-lactose, and spray-dried lactose 
are obtained, respectively. The three different lactose grades differ considerably in their 
mechanical properties in relation to tableting. For instance, anhydrous b-lactose shows a steep 
compression force–tablet crushing strength relation. On the other hand, a-lactose monohydrate 
and even spray-dried lactose are inferior grades in this respect. Spray drying of lactose forms 
partial amorphous structures, and that contributes to its better compressibility. Spray-dried 
lactose flows well because of its spherical granule shape. Therefore, the mechanical properties 
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and the size distribution of lactose types must be known before making a selection out of many 
lactose grades. A partial list of excipientsused in tablet manufacturing is following: 
 
1.4.7 Binders 
Binders in tablet technology serve the purpose of binding small drug or excipient 
particles together to impart cohesiveness, and to form a granulate of a designed size range, 
usually larger than the initial material that flows freely and is also compressible, and eventually 
to be compressed into tablets or to be filled into capsules. A binder will help the tablet to remain 
intact after compression. Binders can be added as dry powders to form a matrix that will include 
the drug, as in the case of dry granulation or in direct compression. Sometimes, the binders are 
dissolved in liquids such as water or alcohol and then sprayed onto the powder mixture as with 
wet granulation. Materials such as MCC act as a binder/ diluent in the case of direct 
compression. However, a polymer such as PVP is solely used as a binder. One of the commercial 
products of PVP is KollidonTM(BASF), which has grades on the basis of molecular weight of 
the polymer: Kollidon K 25 (MW 28,000–34,000), K 30 (MW 44,000–54,000), and K 90 (MW 
1,000,000–1,500,000) contain PVP of increasing molecular weights. PVP has some advantages 
over other binders: it is used in relatively small concentrations such as 1% to 5% to prepare a 
binder solution, itis soluble to above 10% in water, ethanol, and glycerol, which provides an 
opportunity for water-free granulation. One of the most significant advantages of PVP is its low 
viscosity (5–10 mPa.sec) even up to concentrations as high as 20% (w/v). A low-viscosity 
solution can easily be sprayed using peristaltic pumps during a fluidized-bed granulation. Starch 
paste has been a traditional binder, at concentrations between 5% and 10%. Starch is dispersed in 
cold water, and then slowly heated up to boiling with constant stirring. When a translucent paste 
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is formed, it can be diluted with cold water. On the other hand, preparing a starch paste with 
modified starch will not require boiling, since it dissolves in warm water because of the free 
amylopectin. In modern granulation processes using highshearmixers, starch paste finds few 
applications. HPMC, MC, HPC, and ethyl cellulose can be used as binders in tablet formulations. 
These cellulose-based binders perform as well as PVP in modern granulation processes. 
Hydrophilic polymers, especially of low molecular weight, for instance HPMC E6 (6 cP 
viscosity grade), can be dissolved in water to obtain a low-viscosity solution, and they bind well 
and contribute to plastic deformation during tableting. The high-molecular weight grades of 
these cellulose based materials can be used as matrix formers, and incorporated into formulations 
as dry binders. Ethyl cellulose is not water soluble, so it is used as an alcoholic solution. 
Materials such as PVP and HPMC have largely replaced other binders such as gelatine, sucrose, 
simple syrup, or acacia. 
 
1.4.8 Disintegrants 
Disintegrants serve the purpose of facilitating the disintegration of tablets into 
itsComponents either after administration in the GI tract or just before administration, suchAs in 
the case of the fast-disintegrating tablets. Disintegrants may play an important role in the 
bioavailability of a drug in tablet dose forms. When disintegrantscome into contact with water, 
they usually swell, as their cross-linked molecular structure, such as in amylose in starch or in 
cross-linked PVP, imbibes water and swells, providing the force to disperse the tablet. 
Depending on the formulation design, some tablets containing higher percentages of MCC may 
disintegrate readily during disintegration tests without an additional disintegrant. Addition of 
starches externally to the final granulation before tableting is best justified for disintegration 
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purposes. Starch is a “mild” tablet disintegrant. In the past, there was concern that tablet 
compression forces should not exceed certain limits or tablet crushing strengths 70 to 80 N 
because of the probability of prolonged disintegration times. However, with the advent of 
modern excipients, mechanically strong tablets with 200 to 300 N crushing strengths can be 
produced, and these tablets will disintegrate within five minutes or less using the super-
disintegrants. Super-disintegrants are materials added to tablet formulations in a range of 1% to 
5% to assure disintegration within 1 to 10 minutes. Among these are sodium carboxymethyl 
starch (ExplotabTM, Mendell, U.S.A.), cross-linked sodium carboxymethylcellulose 
(PharmacelTM XL, DMV, Netherlands), and cross-linked PVP (17) (KollidonTMXL, BASF). 
The rank order of the degree of swelling in water in two minutes for those disintegrants has been 
reported to be sodium carboxymethyl starch >sodium carboxymethyl cellulose > L-HPC 11 > 
cross-linked PVP > starch > MCC. 
 
1.4.9 Lubricants 
Pharmaceutical lubricants are materials used in tablet formulations to reduce the friction 
Between the lower punch and the die and the tablet. Friction damages both the tablet and the 
tablet press during the ejection cycle. Lubricants are a mechanical necessity, without which 
modern tablet manufacturing would be impossible. Glidants are materials that reduce 
interparticular friction, covering the particle surfaces with a thin layer, and as a result helping in 
better granule flow. Colloidal silicon dioxide, talc, and starch can be used as glidants; colloidal 
silicon dioxide is effective as low as 0.5% as a glidant. Lubricants are added to pharmaceutical 
granules just before the tableting stage. Mixing the main granule mass with a lubricant has been 
an intensively investigated subject. Prolonged mixing with a surface-covering lubricant such as 
Formulation development &in-vitro evaluation of potassium chloride extended release tablets 
Department of Pharmaceutics 20 JKKMMRF’s College Pharmacy 
magnesium stearate negatively affects the binding capacity of a granule mass. Hence, tablet 
formation might be inhibited, unless the granule mass undergoes brittle fracture and creates new 
clean surfaces. Especially, materials exhibiting plastic deformation with a limited surface area 
Would show a strong sensitivity to lubricants. Therefore, the specific surface area of a lubricant 
as well as the surface area of the granule mass are both important parameters in selecting 
lubricant type, concentration, and mixing times. Boundary lubricants will adhere on the metal 
surfaces of the tablet press, die, and punches and will form a boundary layer with the tablet. 
Alkaline stearates such as magnesium stearate are an example of a boundary lubricant. 
Magnesium stearate is still the most effective pharmaceutical lubricant. Its usual concentration 
range is between 0.1% and 2%, and its effectiveness shows a biphasic profile, a region of a fast 
reduction in friction up to 1 %, and a slower friction-reducing effect after 1%. Magnesium 
stearate reduces not only the lower punch ejection force by about 70% but also tablet tensile 
strength. Stearic acid is the second most important lubricant. It is not as effective as magnesium 
stearate, the minimum effective stearic acid concentration is about 1%, and it reduces the lower 
punch ejection force no more than 30%. This fatty acid is however useful when an alkaline 
ingredient in a tablet formula is undesirable. The hexagonal form of boron nitride (HBN) has 
been reported as a potential tablet lubricant. HBN is similar to graphite, which is soft and 
lubricious. This inorganic solid powder retains its ability to lubricate in extreme cold or heat.It 
was reported that boron nitride reduced the lower punch ejection force as efficiently as 
magnesium stearate, but its ability to reduce the tablet tensile strength is less than magnesium 
stearate. The result is mechanically stronger tablets. Therefore, there is a good potential for HBN 
to be used as a tablet lubricant. For effervescent tablets, water-soluble lubricants are required 
since insoluble alkaline lubricants would accumulate on the surface of final solution or form a 
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cloudy solution with an alkaline taste, all of which is undesirable. Sodium lauryl sulfate, DL-
leucine, or various PEGs can be used as water-soluble lubricants. Liquid paraffin and 
hydrogenated vegetable oil are also among the lubricants, but their effectiveness is lower than 
that of magnesium stearate and stearic acid.[3]  
1.5 TABLET-MANUFACTURING OPERATIONS: 
There are three general methods of tablet preparation. 
¾ Direct compression method 
¾ Dry granulation method 
¾ Wet granulation method 
1.5.1 Direct compression 
Direct compression is the process by which tablets are compressed directly from powder 
mixture of API and suitable excipients. This method of tablet making is of special interest for 
small group of crystalline chemicals having the entire physical characteristic necessary for the 
formulation of a good tablet. 
¾ Advantages 
1. The most important advantage of direct compression is economical process. Reduced 
processing times, reduced labors costs, fewer manufacturing steps and less number of 
equipment’s are required, less process validation, reduced consumption of power. 
2. Elimination of heat and moisture, thus increasing not only the stability but also the 
suitability of the process for themolabile and moisture sensitive API’s. 
3. Particle size uniformity. 
4. The chances of batch-to-batch variation are negligible, because the unit operations 
required for manufacturing processes is fewer. 
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5. Chemical stability problems for API and excipients would be avoided. 
6. Provides stability against the effect of aging which affects the dissolution rates. 
¾ Disadvantages 
1. Problems in the uniform distribution of low dose drugs. 
2. The choice of excipients for direct compression is extremely critical. Direct compression 
diluents and binders must possess both good compressibility and good flowability. 
3. Many active ingredients are not compressible either in crystalline or amorphous forms. 
4. Direct compression blends may lead to unblending because of difference in particle size 
and density of drug and excipients. Similarly the lack of moisture may give rise to static 
charges, which may lead to unblending. 
5. Non-uniform distribution of colour, especially in tablets of deep colours. 
1.5.2 Dry granulation method 
This process of granulation is also known as slugging, double compression or 
recompression method. This process of tablet preparation is commonly used when the tablet 
ingredients are sensitive to moisture or are unable to withstand elevated temperature during 
drying. Under such conditions dry granulation is the method of choice provided the tablet 
ingredients have sufficient inherent binding or cohesive properties. 
¾ Advantages 
1. It uses less equipment’s and space. 
2. It eliminates the need for binder solution, heavy mixing equipment and the costly and 
time consuming drying step required for wet granulaion. 
3. It can be used for moisture sensitive and heat sensitive materials. 
4. For improved disintegration since powder particles are not bonded together by a binder. 
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¾ Disadvantages 
1. It requires a specialized heavy duty tablet press to form slug. 
2. It does not permit uniform colour distribution as can be achieved with wet granulation 
where the dye can be incorporated into binder liquid. 
3. The process tends to create more dust than wet granulation, increasing the potential 
contamination. 
1.5.3 Wet granulation method 
Wet granulation process simply involves wet massing of the powder blend with a granulating 
liquid, wet sizing and drying. 
¾ Advantage 
1. It is a robust process suitable for most compounds. 
2. It imparts flowability to a formulation. 
3. It can reduce elasticity problems. 
4. In this process drug binds with excipients, thus reduces segregation potential. 
5. Non aqueous wet granulation process is suitable for moisture sensitive drugs. 
¾ Disadvantages 
1. The greatest disadvantage of wet granulation is its cost. It is an expensive process 
because of labour, time, equipment, energy and space requirements. 
2. Loss of material during various stages of processing. 
3. Stability may be major concern for moisture sensitive or thermo labile drugs. 
4. Multiple processing steps add complexity and make validation and quality control difficult. 
5. An inherent limitation of wet granulation is that any incompatibility between formulation 
components is aggravated.[6] 
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1.6 MECHANISM OF GRANULE FORMATION: 
Granules are formed in three stages: 
1.6.1 Nucleation; 
Here, the particles adhere due to liquid bridges which are the initiation step of Granulation. 
These adhered particles play a role of nucleus for further enlargement of granules. 
1.6.2 Transition; 
Enlargement of nucleus takes place by two possible mechanisms. Individual particle adhere to 
the nucleus or two or more nuclei combine among themselves. 
1.6.3 Ball growth or enlargement of the granule; 
Ball growth occurs either by Coalescence or Breakage or Abrasion Transfer or Layering. In 
Coalescence a larger granule is formed when two or more granules are united. In Breakage 
granules break and the fragments of granule adhere to other granules. This forms a layer of 
material over intact granules. In Abrasion Transfer granule material are abraded through attrition 
by the agitation of granule bed and abraded material adheres to other granules resulting into 
enlarged granules. In layering particles adheres to the already formed granules increasing their 
size. 
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1.8 TABLET COATING: 
Coating is a process by which an essentially dry, outer layer of coating material is applied to the 
surface of a dosage form in order to confer specific benefits that broadly ranges from facilitating 
product identification to modifying drug release from the dosage form. After making a good 
tablet, one must often coat it. Coating may be applied to a wide range of oral solid dosage form, 
including tablets, capsules, multiparticulates and drug crystals. When coating composition is 
applied to a batch of tablets in a coating pan, the tablet surfaces become covered with a tacky 
polymeric film. Before the tablet surface dries, the applied coating changes from a sticky liquid 
to tacky semisolid, and eventually to a non sticky dry Surface pans. The entire coating process is 
conducted in a series of mechanically operated acorn-shaped coating pans of galvanized iron 
stainless steel or copper. The smaller pans are used for experimental, developmental, and pilot 
plant operations, the larger pans for industrial production 
1.8.1 Basic principles involve in tablet coating 
Tablet coating is the application of coating composition to moving bed of tablets with 
concurrent use of heated air to facilitate evaporation of solvent. 
a. Solution in which influences the release pattern as little as possible and does not markedly 
change the appearance. 
b. Modified release with specific requirement and release mechanism adapted to body function 
in the digestive tract. 
c. Color coating which provides insulation. 
d. To incorporate another drug or formula adjuvant in the coating to avoid chemical 
incompatibilities or to provide sequential drug release. 
e. To improve the pharmaceutical elegance by use of special colors and contrasting printing. 
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1.8.2 Film-coated tablets 
A film-coated tablet is covered with a thin layer of resins, polymers and/or plasticizers 
capable of forming a film. 
1.8.2.1 Disintegration test 
Film-coated tablets comply with 5.3 Disintegration test for tablets and capsules. Operate 
the apparatus for 30 minutes, and examine the state of the tablets.[12] 
1.9 QUALITY CONTROL OF TABLETS: 
After manufacturing tablets, a series of tests are carried out to assure that they meet the 
Specifications of pharmacopoeia or industry standards. These tests are as listed below: 
¾ Crushing strength 
¾ Disintegration 
¾ Friability 
¾ Dissolution 
¾ Drug content uniformity 
¾ Weight uniformity 
¾ Weight and thickness 
Some tablets are ready to be used after manufacture, while some need to be coated For further 
functional properties such as enteric coating or controlled-release coating.[7] 
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2 LITERATURE REVIEW 
2.1 Lloyd N et al; The use of extended-release products offers some potential advantages in 
patient convenience/compliance and therapeutic outcomes. However, the range of drugs for 
which clinically significant advantages have been shown is limited. Prescribers and pharmacists 
should be aware of the costs of these products and have a knowledge of their clinical use in 
selected patient groups. In some instances, the formulation is probably serving a marketing 
objective rather than a clinical objective. 
2.2Navin Dixit et al; The oral route is the most popular route used for administration of drugs, 
which is due in part to the ease of administration and to the fact that gastrointestinal physiology 
offers more flexibility in dosage form design than most other routes. The terms Sustained 
release, prolonged release, modified release, extended release or depot formulations are used to 
identify drug delivery systems that are designed to achieve or extend therapeutic effect by 
continuously releasing medication over an extended period of time after administration of a 
single dose. There are several reasons for attractiveness of these dosage forms: provides 
increased bioavailability of drug product, reduction in the frequency of administration to prolong 
duration of effective blood levels, reduces the fluctuation of peak trough concentration and side 
effects and possibly improves the specific distribution of the drug. 
2.3 K.P. Sampath Kumar et al;Pharmaceutical invention and research are increasingly focusing 
on delivery systems which enhance desirabletherapeutic objectives while minimizing side 
effects. Oral drug delivery system represents one of the frontier areasof controlled drug delivery 
system. Such a dosage forms having a major advantage of patient compliance. Sustainedrelease 
dosage forms are designed to release a drug at a predetermined rate in order to maintain a 
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constant drug concentration for a specific period of time with minimum side effects. Now a days 
as very few drugs are coming out of research and development and already existing drugs are 
suffering the problem of resistance due to their irrational use specifically in case of drugs like 
antibiotics. Hence, change in the operation is a suitable and optimized way to make the some 
drug more effective by slight alteration in the drug delivery. Sustained Release is also providing 
promising way to decrease the side effect of drug by preventing the fluctuation of the therapeutic 
concentration of the drug in the body. 
2.4 Christenson et al; This invention provides extended release potassium chloride granules 
consisting essentially of potassium chloride crystals having a mesh size of about 20—60 mesh 
that are coated only With ethyl cellulose. The granules may be compressed into tablets that 
disintegrate rapidly in an aqueous environment to provide uniform dissolution of the potassium 
chloride. Tablets containing about 10 to about 20 milliequivalents potassium may be formulated 
in accordance With the invention. Processes to produce extended release granules without using 
surfactants, processing aids or other coating aids are also provided by this invention. A method is 
further provided whereby a patient’s supplemental potassium requirements are met by 
administering an appropriate combination of dosage units chosen from available dosage units 
containing different quantities of potassium. 
2.5Alsop WR, et al; the effects on the upper gastrointestinal tract of five different preparations 
of KCl were compared in 90 healthy subjects treated with glycopyrrolate. The KCl preparations 
studied were wax-matrix KCl, microencapsulated KCl, liquid KCl, experimental extended-
release capsules, experimental extended-release tablets, and placebo. The subjects were 
endoscoped prior to and after seven days of dosing. Upper gastrointestinal mucosal pathology 
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was seen with all of the potassium preparations as well as with placebo. No statistically 
significant differences between the various KCl groups or between KCl groups and placebo were 
seen. All of the lesions were superficial, except for one ulcer seen with the microencapsulated 
KCl. None of the subjects developed occult gastrointestinal bleeding. There were no differences 
in the incidence of abdominal symptoms. 
2.6 Dr. D. M. Patel et al; the objective of the present study was to evaluate the effect of 
sintering condition on matrix formation and subsequent drug release from polymer matrix tablet 
for controlled release. The present study highlights the use of a microwave oven for the sintering 
process in order to achieve more uniform heat distribution with reduction in time required for 
sintering. We could achieve effective sintering within 8 min which is very less compared to 
conventional hot air oven sintering. The tablets containing the drug (propranolol hydrochloride) 
and sintering polymer, were prepared and kept in a microwave oven at 540 watt, 720 watt and 
900 watt power for different time periods for sintering. The sintered tablets were evaluated for 
various tablet characteristics including dissolution study. Tablets sintered at 900 watt power for 8 
min gave better dissolution profile compared to others. We conclude that microwave oven 
sintering is better than conventional hot air oven sintering process in preparation of controlled 
release tablets. 
 
2.7 Monica Rao et al; The present research studied the effect of sintering technique in the 
development of a controlled release formulation for ketorolac tromethamine. The method 
consisted of mixing drug and wax powder (Compritol® 888 ATO) along with lactose as diluent 
and talc as lubricant followed by direct compression at room temperature. The compressed fluffy 
matrices were kept at 80°C for 1, 2, and 3 h forsintering. The sintered tablets were characterized 
Formulation development &in-vitro evaluation of potassium chloride extended release tablets 
Department of Pharmaceutics 32 JKKMMRF’s College Pharmacy 
by their physical parameters and in vitro dissolution profile. The sintering time markedly 
affected the drug release properties of Compritol® 888 ATO matrices. It is notable that the 
release rate of ketorolac tromethamine from matrices was inversely related to the time of 
sintering. This may be due to the increase in the extent and firmness of sintering which further 
compacts the mass so that drug release is affected. Contact angle measurement and scanning 
electron microscopy analysis indicated that heat treatment caused the wax to melt and 
redistribute. This redistributed wax formed a network-like structure in which the drug along with 
lactose is entrapped. This particular formed matrix is responsible for retarding the drug release. 
Fourier transform infrared spectroscopy results did not show any drug–wax interaction due to 
sintering. Differential scanning calorimetric and powder X-ray diffraction studies ruled out the 
occurrence of solid solution and polymorphic changes of the drug. Drug release from the wax 
tablets with or without sintering was best described by the Higuchi equation. 
 
2.8 Sunil Kumar et al; Oral drug delivery is the most preferred route for the various drug 
molecules among all other routes of drug delivery, because ease of administration which lead to 
better patient compliance. So, oral extended release drug delivery system becomes a very 
promising approach for those drugs that are given orally but having the shorter half-life and high 
dosing frequency. Extended release drug delivery system which reduce the dosing frequency of 
certain drugs by releasing thedrug slowly over an extended period of time. There are various 
physiochemical and biological properties which affect the extended release drug delivery system. 
This article providing the recent literature regarding development and design of extended release 
tablets. 
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2.9 K. P. R. Chowdary et al; Formulation and manufacture of matrix tablets is a least 
complicated approach widely used in industry for obtainingoral controlled release. Matrix tablet 
formulation needs an efficient release retarding material, which plays a critical role in regulating 
drug release from matrix tablets. Literature on matrix tablets along with recent research on 
matrix tablets for controlled release is reviewed in this article. 
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3.AIM & OBJECTIVES 
Patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for 
patients in whom there is a problem of compliance with these preparations.  
The aims of the present study were to formulate and evaluate potassium chloride     extended 
release tablets 
 
The study was carried out in the following stages: 
 
¾ To Development and in vitro evaluation of potassium chloride extended release tablets 
¾ To carry out pre-formulation studies 
¾ To carry out the stability studies of the formulated extended release dosage form as per 
ICH guidelines 
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4. PLAN OF WORK 
 
This research work comprises the following 
1. Literature review  
2. Selection of excipients from the reference literature  
3. Selection of excipients quantity from available reference product. 
4. Preformulation studies. 
5. Formulation of Trial Batches. 
6. Evaluation of Pre-compression and Post-compression characteristics. 
7. Selection of final formulation. 
8. Comparison of dissolution profile between finalized potassium chloride formulation  
and reference product. 
9. Stability studies for the finalized potassium chloride formulation. 
10. Comparison of drug release with the reference product. 
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5. MATERIELS AND METHODS 
5.1 List of materials and their manufacturers or suppliers. 
    Table No: 1 
S.No Materials Functions Manufacturers/suppliers 
1. Potassium chloride  Active Ingredient Klinge Chemicals Limited 
2. Hydrogenated vegetable oil  Release controlling agent 
Abitech corporation 
3. Ethocel 100 FP Release controlling agent 
Colorcon asiapvt lid 
4. Ethocel 10 FP Binder Colorcon asiapvt lid 
5. Colloidal silicon dioxide Glidant Cabot Sanmar lid 
6. Talc Glidant& Lubricant Luzenac 
7. Syloid Glidant Grace Davison 
8. Magnesium stearate Lubricant Valerus speciality chemicals 
9. Iso propyl alcohol Solvent Merck  
10. OpadryII85F520112 Yellow Coating material Colorcon asia pvt lid 
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5.2  LIST OF EQUIPMENTS USED 
The following equipment’s and instruments were used in the formulation and development of 
potassium chloride Extended release tablets. 
     Table no: 2 
S. No. NAME OF THE INSTRUMENT MAKE 
1. Analytical balance Sartorius 
2. Electromagnetic Sieve Shaker Electro Lab 
3. Tap Density Apparatus Electro Lab 
4. Moisture Analyzer Sartorius 
5. Tablet Compression Machine Cad Mach 
6. Tablet Coating Machine Siemens 
7. Digital Vernier Caliper Mitutoyo 
8. Disintegration tester Electro Lab 
9. Friability apparatus Electro Lab 
10. Dissolution Electro Lab 
11. HPLC Thermo scientific 
12. Stability Chamber Thermo lab 
13. Fluid bed equipment Pam Glatt 
14. Rapid mixing Granulation Anchor mark 
15. Octagonal  blender Anchor mark 
16. Multi Mill  Anchor mark 
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5.3 EXCIPIENT SELECTION: 
Excipients used in the present work were selected according to innovator excipient list. 
Excipients includes 
¾ Hydrogenated vegetable oil  
¾ Ethocel 100 fp 
¾ Ethocel 10 fp 
¾ Colloidal silicon dioxide 
¾ Talc 
¾ Magnesium stearate 
5.3.1 HYDROGENATED VEGETABLE OIL  
    a) Chemical Name and CAS Registry Number 
¾ Hydrogenated vegetable oil 
¾ Hydrogenated soybean oil 
b) Structural Formula 
R1COOCH2—CH(OOCR2)—CH2OOCR3 
where R1, R2, and R3 are mainly C15 and C17. 
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c) Description: 
Hydrogenated vegetable oil is a mixture of triglycerides of fattyacids. The two types that 
are defined in the USP32–NF27 arecharacterized by their physical properties. Hydrogenated 
vegetable oil type I occurs in various forms, e.g.fine powder, flakes, or pellets. The color of the 
material depends onthe manufacturing process and the form. In general, the material iswhite to 
yellowish-white with the powder grades appearing morewhite-colored than the coarser grades. 
d) Functional Category 
Tablet and capsule lubricant; tablet binder. 
e) Applications in Pharmaceutical Formulation orTechnology 
Hydrogenated vegetable oil type I may be used as a lubricant in tablet and capsule 
formulations. In this application it is used at concentrations of 1–6% w/w, usually in combination 
with talc, silica or a silicate to prevent sticking to tablet punch faces. It may also be used as an 
auxiliary binder in tablet formulations. Hydrogenated vegetable oil type I is additionally used as 
the matrix-forming material in lipophilic-based controlled-release formulations; it may also be 
used as a coating aid in controlled-release formulations. It has also been investigated in 
hydrophobic melt agglomeration. 
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5.3.2 ETHYL CELLULOSE 
a) Chemical Name and CAS Registry Number 
Cellulose ethyl ether  
b) Molecular structure 
 
c) Description 
Ethylcellulose is a tasteless, free-flowing, white to light tan-colored powder. 
d) Functional Category 
Coating agent; flavoring agent; tablet binder; tablet filler; viscosity increasing agent. 
e) Method of Manufacture 
Ethylcellulose is prepared by treating purified cellulose (sourced from chemical-grade 
cotton linters and wood pulp) with an alkaline solution, followed by ethylation of the alkali 
cellulose with chloroethane as shown below, where R represents the cellulose radical: 
 RONa+ C2H5Cl→ROC2H5 +NaCl 
The manner in which the ethyl group is added to cellulose can be described by the degree of 
substitution (DS). The DS designates the average number of hydroxyl positions on the 
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anhydroglucose unit that have been reacted with ethyl chloride. Since each anhydroglucoseunit 
of the cellulose molecule has three hydroxyl groups, the maximum value for DS is three. 
f) Incompatibilities 
Incompatible with paraffin wax and microcrystalline wax. 
g) Applications in Pharmaceutical Formulation or Technology 
Ethylcellulose is widely used in oral and topical pharmaceutical formulations, the main 
use of ethylcellulose in oral formulations is as ahydrophobic coating agent for tablets and 
granules. Ethylcellulose coatings are used to modify the release of a drug, to mask an unpleasant 
taste, or to improve the stability of a formulation; for example, where granules are coated with 
ethylcellulose to inhibit oxidation. Modified-release tablet formulations may also be  produced 
using ethylcellulose as a matrix former. Ethylcellulose, dissolved in an organic solvent or solvent 
mixture, can be used on its own to produce water-insoluble films. Higher-viscosity ethylcellulose 
grades tend to produce stronger and more durable films. Ethylcellulose films may be modified to 
alter their solubility, by the addition of hypromellose or aplasticizer; Drug release through 
ethylcellulose-coated dosage forms can be controlled by diffusion through the film coating. This 
can be a slow process unless a large surface area (e.g. pellets or granules compared with tablets) 
is utilized. In those instances, aqueous ethylcellulose dispersions are generally used to coat 
granules or pellets. Ethylcellulose-coated beads and granules have also demonstrated the ability 
to absorb pressure and hence protect the coating from fracture during compression. 
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5.3.3 COLLOIDAL SILICON DIOXIDE 
a) Chemical Name and CAS Registry Number 
Silica 
b) Description 
Colloidal silicon dioxide is a submicroscopic fumed silica with a particle size of about 15 
nm. It is a light, loose, bluish-white-colored, odorless, tasteless, amorphous powder. 
c) Functional Category 
Adsorbent; anticaking agent; emulsion stabilizer; glidant; suspending agent; tablet 
disintegrant; thermal stabilizer; viscosity-increasing agent. 
d) Incompatibilities 
Incompatible with diethylstilbestrol preparations. 
e) Method of Manufacture 
Colloidal silicon dioxide is prepared by the flame hydrolysis of chlorosilanes, such as 
silicon tetrachloride, at 1800◦C using a hydrogen–oxygen flame. Rapid cooling from the molten 
stateduring manufacture causes the product to remain amorphous. 
f) Applications in Pharmaceutical Formulation or Technology 
Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and food 
products. Its small particle size and large specific surface area give it desirable flow 
characteristics that are exploited to improve the flow properties of dry powdersin a number of 
processes such as tableting and capsule filling. Colloidal silicon dioxide is also used to stabilize 
emulsions and as a thixotropic thickening and suspending agent in gels and semisolid 
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preparations. With other ingredients of similar refractive index, transparent gels may be formed. 
The degree of viscosity increase depends on the polarity of the liquid (polar liquids generally 
require a greater concentration of colloidal silicon dioxide than nonpolar liquids). Viscosity is 
largely independent of temperature. However, changes to the pH of a system may affect the 
viscosity. In aerosols, other than those for inhalation, colloidal silicon dioxide is used to promote 
particulate suspension, eliminate hard settling, and minimize the clogging of spray nozzles. 
Colloidal silicon dioxide is also used as a tablet disintegrant and as an adsorbent dispersing agent 
for liquids in powders. Colloidal silicon dioxide is frequently added to suppository formulations 
containing  lipophilic excipients to increase viscosity, prevent sedimentation during molding, and 
decrease the release rate. Colloidal silicon dioxide is also used as an adsorbent during the 
preparation of wax microspheres; as a thickening agent for topical preparations and has been 
used to aid the freeze-drying of nanocapsules and nanosphere suspensions. 
5.3.4 TALC 
a) Chemical Name and CAS Registry Number  
Talc 
b) Functional Category 
Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule lubricant. 
c) Description 
Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, crystalline powder. It 
adheres readily to the skin and is soft to the touch and free from grittiness. 
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d) Incompatibilities 
Incompatible with quaternary ammonium compounds. 
 e) Method of Manufacture 
Talc is a naturally occurring hydropolysilicate mineral found in many parts of the world 
including Australia, China, Italy, India, France, and the USA. The purity of talc varies depending 
on the country of origin. For example, Italian types are reported to contain calcium silicate as the 
contaminant; Indian types contain aluminum and iron oxides; French types contain aluminum 
oxide; and American types contain calcium carbonate (California), iron oxide (Montana), 
aluminium and iron oxides (North Carolina), or aluminum oxide (Alabama).Naturally occurring 
talc is mined and pulverized before being subjected to flotation processes to remove various 
impurities such as asbestos (tremolite); carbon; dolomite; iron oxide; and various other 
magnesium and carbonate minerals. Following this process, the talc is finely powdered, treated 
with dilute hydrochloric acid, washed with water, and then dried. The processing variables of 
agglomerated talc strongly influence its physical characteristics. 
f) Applications in Pharmaceutical Formulation or Technology 
Talc was once widely used in oral solid dosage formulations as a lubricant and diluent, although 
today it is less commonly used. However, it is widely used as a dissolution retardant in the 
development of controlled-release products. Talc is also used as a lubricant in tablet 
formulations; in a novel powder coating for extended-release pellets; and as an adsorbant. In 
topical preparations, talc is used as a dusting powder, although it should not be used to dust 
surgical gloves. Talc is a natural material; it may therefore frequently contain microorganisms 
and should be sterilized when used as a dusting powder, Talc is additionally used to clarify 
liquids and is also used in cosmetics and food products, mainly for its lubricant properties. 
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5.3.5 MAGNESIUM STEARATE 
a) Chemical Name and CAS Registry Number 
Octadecanoic acid magnesium salt 
b) Structural Formula 
[CH3 (CH2)16COO] 2Mg 
c)Functional Category 
Tablet and capsule lubricant. 
d)Incompatibilities 
Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with strong oxidizing 
materials. Magnesium stearate cannot be usedin products containing aspirin, some vitamins, and 
most alkaloidal salts. 
 e) Method of Manufacture 
Magnesium stearate is prepared either by the interaction of aqueous solutions of magnesium 
chloride with sodium stearate or by the interaction of magnesium oxide, hydroxide, or carbonate 
with stearic acid at elevated temperatures. 
f) Description 
Magnesium stearate is a very fine, light white, precipitated or milled, impalpable powder 
of low bulk density, having a faint odour of stearic acid and a characteristic taste. The powder is 
greasy to the touch and readily adheres to the skin. 
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g) Applications in Pharmaceutical Formulation or Technology 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical formulations. 
It is primarily used as a lubricant in capsule and tablet manufacture at concentrations between 
0.25%and 5.0% w/w. It is also used in barrier creams.[3] 
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6.1 INDICATIONS AND USAGE 
Because of reports of intestinal and gastric ulceration and bleeding with controlled-
release potassium chloride preparations, these drugs should be reserved for those patients who 
cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in 
whom there is a problem of compliance with these preparations.  
¾ For the treatment of patients with hypokalemia with or without metabolic 
alkalosis, in digitalis intoxication, and in patients with hypokalemic familial 
periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration 
should be given to the use of a lower dose of diuretic, which may be sufficient 
without leading to hypokalemia.  
¾ For the prevention of hypokalemia in patients who would be at particular risk if 
hypokalemia were to develop, eg, digitalized patients or patients with significant 
cardiac arrhythmias.  
The use of potassium salts in patients receiving diuretics for uncomplicated essential 
hypertension is often unnecessary when such patients have a normal dietary pattern and when 
low doses of the diuretic are used. Serum potassium should be checked periodically, however, 
and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be 
adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is 
ineffective or unwarranted, supplementation with potassium salts may be indicated.[17] 
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6.2  DOSAGE ADMINISTRATION: 
The usual dietary potassium intake by the average adult is 50 to 100 mEq per day. 
Potassium depletion sufficient to cause hypokalemia usually requires the loss of 200 or more 
mEq of potassium from the total body store. Dosage must be adjusted to the individual needs of 
each patient. The dose for the prevention of  hypokalemia is typically in the range of 20 mEq per 
day. Doses of 40-100 mEq per day or more are used for the treatment of potassium depletion. 
Dosage should be divided if more than 20 mEq per day is given such that no more than 20 mEq 
is given in a single dose. Potassium Chloride extended-release tablets provide 8 mEq, 10 mEq 
and 20 mEq of Potassium Chloride. 
Potassium Chloride extended-release tablets should be taken with meals and with a glass 
of water or other liquid. This product should not be taken on an empty stomach because of its 
potential for gastric irritation (see WARNINGS). 
(NOTE: Potassium Chloride extended-release tablets are to be swallowed whole without 
crushing, chewing or sucking the tablets.) 
6.3 CLINICAL PHARMACOLOGY: 
6.3.1 MECHANISM OF ACTION: 
Supplemental potassium in the form of high potassium food or potassium chloride may be able 
to restore 
6.3.2 ABSORPTION AND DISTRIBUTION: 
Potassium is a normal dietary constituent and under steady-state conditions the amount of 
potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. 
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6.3.3 METABOLISM AND EXCRETION:  
Supplemental potassium in the form of high potassium food or potassium chloride may be able 
to restore normal potassium.[18] 
 
6.4 PHARMACODYNAMICS: 
The potassium ion is in the principle intracellular cation of most body tissues. Potassium ions 
participate in a number of essential physiological processes including the maintenance of 
intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and 
smooth muscle, and the maintenance of normal renal function. The intracellular concentration of 
potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 
3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma 
membrane. Potassium is a normal dietary constituent and under steady-state conditions the 
amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in 
the urine. The usual dietary intake of potassium is 50 to 100 mEq per day. Potassium depletion 
will occur whenever the rate of potassium loss through renal excretion and/or loss from the 
gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops as a 
consequence of therapy with diuretics, primarily or secondary hyperaldosteronism, diabetic 
ketoacidosis, or inadequate replacement of potassium in patients on prolonged parenteral 
nutrition. Depletion can develop rapidly with severe diarrhea, especially if associated with 
vomiting. Potassium depletion due to these causes is usually accompanied by concomitant loss of 
chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may 
produce weakness, fatigue, disturbances of cardiac rhythm (primarily ectopic beats), prominent 
U-waves in the electrocardiogram, and, in advanced cases, flaccid paralysis and/or impaired 
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ability to concentrate urine. If potassium depletion associated with metabolic alkalosis cannot be 
managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires 
long-term diuretic therapy, supplemental potassium in the form of high potassium food or 
potassium chloride may be able to restore normal potassium levels. In rare circumstances (e.g., 
patients with renal tubular acidosis) potassium depletion may be associated with metabolic 
acidosis and hyperchloremia. In such patients, potassium replacement should be accomplished 
with potassium salts other than the chloride, such as potassium bicarbonate, potassium citrate, 
potassium acetate, or potassium gluconate.[38] 
 
6.5  WARNINGS: 
¾ Upset stomach, nausea, vomiting, gas, or diarrhea may occur. If any of these effects 
persist or worsen, tell your doctor or pharmacist promptly. 
¾ An empty tablet or capsule shell may appear in your stool. This effect is harmless 
because your body has already absorbed the medication. 
¾ Remember that your doctor has prescribed this medication because he or she has judged 
that the benefit to you is greater than the risk of side effects. Many people using this 
medication do not have serious side effects. 
¾ Tell your doctor right away if you have any serious side effects, including: 
difficult/painful swallowing, feeling as if the capsule/tablet is stuck in your throat. 
¾ Get medical help right away if you have any very serious side effects, including: vomit 
that looks like coffee grounds, stomach/abdominal pain, black/tarry stools. 
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¾ A very serious allergic reaction to this drug is rare. However, get medical help right away 
if you notice any symptoms of a serious allergic reaction, including: rash, 
itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble 
breathing. 
6.6 PRECAUTIONS: 
¾ Before taking potassium, tell your doctor or pharmacist if you have any allergies. This 
product may contain inactive ingredients, which can cause allergic reactions or other 
problems. Talk to your pharmacist for more details. 
¾ Before using this medication, tell your doctor or pharmacist your medical history, 
especially of: heart problems, kidney problems, high levels of potassium in the blood. 
¾ Due to rare reports of stomach/intestinal ulcers and bleeding with sustained-release 
potassium products, taking a liquid form of potassium is preferred. Tell your doctor or 
pharmacist if you have throat/stomach/intestinal problems such as blockage, narrowing, 
or ulcers. 
¾ Before having surgery, tell your doctor or dentist about all the products you use 
(including prescription drugs, nonprescription drugs, and herbal products). 
¾ Before using other potassium supplements or salt substitutes that contain potassium, 
consult your doctor or pharmacist. Too much potassium may cause serious side effects. 
(See also Overdose section.) 
¾ During pregnancy, this medication should be used only when clearly needed. Discuss the 
risks and benefits with your doctor. 
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¾ Potassium passes into breast milk. Consult your doctor before breast-feeding. 
¾ Orally, potassium chloride is toxic in excess; the LD50 is around 2.5 g/kg (meaning that a 
lethal dose for 50% of people weighing 75 kg (165 lb) is about 190 g (6.7 ounces)). 
However, this is not far from oral toxicity of sodium chloride (table salt), of 3.75 g/kg, 
thus potassium chloride is harmless for alimentation (and even good for health, see 
previous paragraph). But intravenously, without the step of digestive absorption, this is 
reduced to just over 30 mg/kg.[15] Most concerns are its severe effects on the cardiac 
muscles: high doses can cause cardiac arrest and rapid death, thus the aforementioned use 
as the third and final drug delivered in the lethal injection process.[46] 
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6.7 ACTIVE PHARMACEUTICAL INGREDIENT (API) SPECIFICATION 
Table: 4 API Characterization 
S.NO. TESTS VALUES 
1 Appearance white crystalline 
solid 
2 Solubility in water 281 g/L (0 °C) 
344 g/L (20 °C)    
567 g/L (100 °C) 
3 Heavy metals <10ppm 
4 Water content (by KF) 74.9 
5 Assay (on anhydrous basis, by 
HPLC) 
99.66% 
 
 
 
 
6.8 REFERENCE PRODUCT COMPOSITION & CHARACTERIZATION: 
 
Figure: 5 Picture of reference kcl ER tablets 
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Table No: 5 Reference Products details  
Product Klor-Con 10 mEq 
Label claim Each tablet contains                                                            Potassium Chloride  750 mg   
NDC 0245-0041-11 
Lot.No 310261 
ExpDt 06-18 
Manufactured By Upsher -Smith laboratories inc 
Storage 
Store at controlled room temperature, 15-30°C (59-86°F). 
Protect from light and moisture. Dispense in a tight container 
with child-resistant closure.  
Excipients 
Hydrogenated vegetable oil, magnesium stearate, 
polyethylene glycol, polyvinyl alcohol, silicon dioxide, talc 
and titanium dioxide. Yellow tablets also contain D&C 
Yellow No. 10 aluminum lake and FD&C Yellow No. 6 
aluminum lake.  
Coated Tablet   
Description Yellow round tablets debossed with 'KC 10' 
Avgwt 1016 mg (996-1030 mg) 
Diameter 13 mm 
Thickness 6.35-6.40 mm 
Hardness 90-110N 
D.T Up to three hours disintegration is not observed 
Core Tablet   
Avgwt 980 mg 
Diameter 12.7 mm 
Thickness 6.35-6.40 mm 
Hardness 80-90N 
Pack  100  Tablets in 150 CC HDPE bottle 
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7. EVALUATION PARAMETERS 
7.1 BLEND CHARACTERISTICS: 
The characteristics of a tablet that make it a popular dosage form. E.g. compactness, 
physical stability, rapid production capability, chemical stability and efficacy are in general 
dictated primarily by the qualities of the granulation from which it is made. Basically stated, 
materials intended for compaction into a tablet must possess two characteristics - Fluidity and 
compressibility. To a great extent these properties are required by the compression machine 
design. Thus good flow properties are a prerequisite for the successful manufacture of tablets. It 
is a property of all powders to resist the differential movement between particles when subjected 
to external stresses. This resistance is due to the cohesive forces between the particles. Tablets 
require the flow of the correct weight of material into a specific volume, the behaviour of the 
material under pressure is important; and the wetting of the powder is also critical for granulation 
and subsequent disintegration and dissolution of the dosage form. The prepared granules the l 
were subjected to the following tests. 
7.2 BULK DENSITY 
        Bulk density is defined as the mass of a powder divided by the bulk volume.      
¾ Procedure: 
Weighed quantity of blend was transferred into 100ml measuring cylinder without 
tapping. During transfer the volume occupied by granules was measured. Bulk density was 
measured by using formula. 
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Pb=m/vo 
Where; 
Pb : Bulk Density 
m : Mass of the blend 
vo : Untapped Volume 
7.3 TAPPED DENSITY: 
¾ Procedure: 
Weighed quantity of blend was transferred into 100ml measuring cylinder, volume occupied by 
granules was noted down. Then cylinder was subjected to 500/750/and 1250 taps in tapped 
density tester. Volume variation was calculated by using formula. 
Pt = m/vi 
Where; 
Pt :Tapped Density 
m = Mass of the blend. 
vi= Tapped volume. 
7.4 COMPRESSIBILITY INDEX: 
Compressibility is the ability of power to decrease in volume under pressure. 
Compressibility is a measure that obtained from density determination. 
¾ Procedure: 
Weighed quantity of blend was transferred to 100ml of measuring cylinder, volume 
occupied was noted down. Then cylinder was subjected to 500/750 and 1250 taps in tapped 
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density tester the difference between two taps should be less than 2%.The percentage of 
compressibility Index is calculated by using formula. 
CI: (Pt-Pb/ Pt) ×100 
Where; 
CI: Compressibility index 
Pt: Tapped Density 
Pb: Bulk Density 
7.5 HAUSNER’S RATIO:  
It is measurement of frictional resistance of the drug. It was determined by the ratio of 
tapped density and bulk density. 
Hausner’s Ratio: Pt / Pb 
Where; 
Pt: Tapped Density 
Pb: Bulk Density. 
7.6 ANGLE OF REPOSE: 
 Angle of Repose is defined as the maximum angle possible between the surface of a pile 
of the powder and the horizontal plane. 
The angle of repose was calculated by using the formula given below. 
     Angle of Repose (θ) =Tan -1 (h/r) 
    Where, h = height of pile 
      r = radius of the base of the pile 
      θ = angle of repose. 
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7.7 Effect of Angle of Repose, Compressibility index and Hausner’s ratio on Flow property. 
Table No: 6 Precompression property of tablet formulation 
Flow property Angle Of Repose Compressibility 
index (%) 
Hausner’s Ratio 
Excellent 25° - 30° 0-10 1.00 – 1.11 
Good 31° – 35° 11-15 1.12 – 1.18 
Fair - aid not 
needed 
36° – 40° 16-20 1.19 – 1.25 
Passable - may 
hang up 
41° – 45° 21-25 1.26 – 1.34 
Poor - must 
agitate 
46° – 55° 26-31 1.35 – 1.45 
Very poor –
requires more 
agitation 
56° – 65° 32-37 1.46 -1.59 
Very very poor >66° >38 >1.6 
 
7.8 SIEVE ANALYSIS: 
The sieves are arranged according to the coarsest at the top and finest at the bottom. The 
weighed samples of granules are placed on the top sieve. After sieve shaker has completed for a 
predetermined period of time, the materials that have been sieved are collected to check their 
weight, the powder retained on each sieve is weighed and arithmetic mean of sample is 
determined. 
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7.9 GENERAL APPEARANCE:  
The general appearance of a tablet, its identity and general elegance is essential for 
consumer acceptance, for control of lot-to-lot uniformity and tablet-to-tablet uniformity. The 
control of general appearance involves the measurement of size, shape, color, presence or 
absence of odor, taste etc.  
7.9.1 SIZE & SHAPE:   
It can be dimensionally described & controlled. The thickness of a tablet is onlyvariables. 
Tablet thickness can be measured by micro-meter or by other device. Tablet thickness should be 
controlled within a ± 5% variation of standard value.  
The shape and dimensions of compressed tablets are determined by the type of tooling 
during the compression process. At a constant compressive load, tablets thickness varies with 
changes in die fill, particle size distribution and packing of the powder mix being compressed 
and with tablet weight, while with a constant die fill, thickness varies with variation in 
compressive load. Tablet thickness is consistent from batch to batch or within a batch only if the 
tablet granulation or powder blend is adequately consistent in particle size and particle size 
distribution, if the punch tooling is of consistent length, and if the tablet press is clean and in 
good working condition.  
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7.9.2 ORGANOLEPTIC PROPERTIES: 
Colour is a vital means of identification for many pharmaceutical tablets and is also usually 
important for consumer acceptance. The color of the product must be uniform within a single 
tablet, from tablet to tablet and from lot to lot.. 
Odour may also be important for consumer acceptance of tablets. presence of an odor 
may be characteristic of the drug (e.g. vitamins), added ingredients (e.g. flavoring agent) or the 
dosage form (e.g. film-coated tablets). 
Taste is also important for consumer acceptance of certain tablets (e.g. chewable tablets) 
and many companies utilize taste panels to judge the preference of different flavors and flavor 
levels in the development of a product. Taste preference is however subjective and the control of 
taste in the production of chewable tablets is usually based on the presence or absence of a 
specified taste.  
7.10 WEIGHT VARIATION:  
 Composite samples of tablets (usually 10) are taken and weighed throughout the 
compression process.  The composite weight divided by 10 which gives average weight but 
contain usual problems of averaged values. Within the composite sample that has an acceptable 
average weight, there could be tablets excessively over weight or underweight. To alleviate this 
problem British pharmacopeia provides limits for the permissible variations for uncoated and 
coated tablets: 
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Table No: 7 Weight variation tolerances for uncoated and film coated Tablets(USP) 
Average weight of tablet 
(mg) 
% Deviation 
130  or Less 10 
From 130 through 324 7.5 
More than 324 5 
7.11 CONTENT UNIFORMITY 
The Content uniformity test is used to ensure that every tablet contain the amount of drug 
substance intended with little variation among tablets within a batch. Due to increased awareness 
of physiological availability, the content uniformity test has been included in the monographs of 
all coated and uncoated tablets and all capsules intended for oral administration where the range 
of size of the dosage form available include 50mg or smaller sizes. 
7.12 THICKNESS AND DIAMETER: 
The thickness and diameter of 10 tablets were recorded during the process of 
compression using Vernier caliper. 
7.13 HARDNESS: 
Tablets require a certain amount of strength or hardness and resistance to friability and 
withstand mechanical shocks of handling in packaging and shipping. In addition, tablets should 
be able to withstand reasonable abuse when in the hands of the consumer. Tablet hardness has 
been defined as force required to break a tablet in a diametric compression test. To perform this 
test, a tablet is placed between two anvils, force is applied to the anvils and the crushing strength 
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that just causes the tablet to break is recorded. Hardness is thus sometimes termed the tablet 
crushing strength. 
         Several devices operating in this manner have been and continue to be used to test tablet 
hardness: Monsanto tester, Strong-cobb tester, Pfizer tester, Erweka tester and Schleuniger tester. 
7.14  FRIABILITY: 
 The laboratory friability tester is known as the Roche friabilator. It subjects a number of 
tablets to the combined effects of abrasion and shock by utilizing a plastic chamber that revolves 
at 25rpm dropping the tablets a distance of six inches with each revolution. Normally a pre 
weighed tablet sample is placed in the friabilator, which is then operated for 100 revolutions. The 
tablets are then dusted and reweighed. Some chewable tablets are most effervescence tablets 
undergo high friability weight losses, which accounts for the special stack packaging that may be 
required for these types of tablets. When capping is observed on friability testing, the tablet 
should not be considered for commercial use, regardless of the percentage of loss seen. 
The percentage friability was determined by the formula: 
               % friability = W1-W2/ W1 X 100 
Where; 
W1   = Weight of tablets before test 
W2    =   Weight of tablets after test 
Limit:Not more than 1.0% 
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7.15 DISSOLUTION  
Instruments Required: 
i) Dissolution Apparatus. 
ii) High performance liquid chromatography With CAD. 
Dissolution Conditions: 
Apparatus  :    Paddle 
Medium  :  Milli- Q Water 
Volume  :  900 mL 
RPM   :  50 
 Temperature  :  37 ± 0.50 C 
 Time points  :  1, 2, 4, 6, 8, 12, 16& 150 RPM 
Preparation of 0.2 M Ammonium Acetate: 
 Weighed and transfer 15.4g of Ammonium Acetate into 1000 mL volumetric flask. 
Dissolve and dilute volume with water, adjust pH to 4.0 with acetic acid. 
Mobile Phase A :  100 % Acetonitrile 
Mobile Phase B :  100 % Water. 
Mobile Phase C :  0.2 M Ammonium Acetate Buffer. 
 Potassium Chloride Standard Preparation: (750 mg) 
 Weighed and transferred 42.0 of potassium chloride standard into 50 mL flask, added 30 
ml dulcet and sonicate 5.0 mins and diluted volume with diluents. Filtered through 0.45 filtr.  
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Sample Preparation:  
 Switch on the dissolution apparatus and fill the washed bowls with 900 ml each of 
dissolution media. 
Allow the dissolution medium to attain the temperature of 37 ° C +/0.50 C. 
Place six tablets separately in six bowls and start the instrument. 
After the specified time withdraw required quantity of sample from a zone midway between the 
surface of the dissolution medium and top of the rotating paddle not less than 1 cm from the 
vessel wall. 
Filter the sample through 0.45 μ nylon membrane filter. 
Discard the first few ml of filtrate. 
Collect the filtrate, and use as sample solution. 
Procedure: 
Before starting the system equilibrate the column with gradient composition at least 2 Hours. 
Inject gradient (1 injection), Blank (1 injection), 6 Standard preparation and check for system 
suitability parameters, 
The% RSD for area response of 6 replicate injection should be not more than 5.0 % 
Tailing factor for potassium standard peak should not be more than 2.0 
If system suitability parameters pass inject sample preparation one injection into chromatograph. 
Record the chromatograms. 
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Note: Calculate the sum area response of potassium and chloride peaks. 
Calculation: 
 LC
100
100
P
1
DT
DS
WS
AS
AT ××××=  
Where, 
AT : The sum Area of potassium and chloride peak from sample chromatogram. 
As : The sum Area of potassium and chloride peak from standard chromatogram. 
Ws : Weight of potassium chloride standard in mg. 
Ds : Dilution of standard solution. 
Dt : Dilution of sample solution. 
P : Potency of potassium chloride standard 
LC : Label claim of potassium chloride in mg per tablet.[6] 
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7.16 ASSAY :( BY HPLC) 
Instruments Required: 
 i)    High performance liquid chromatography With CAD. 
Preparation of 0.2 M Ammonium Acetate: 
 Weighed and transfer 15.4g of Ammonium Acetate into 1000 ml volumetric flask. 
Dissolve and dilute volume with water, adjust PH to 4.0 with acetic acid. 
Mobile Phase A : 100 % Acetonitrile 
Mobile Phase B : 100 % Water. 
Mobile Phase C : 0.2 M Ammonium Acetate Buffer. 
 Potassium chloride Standard preparation:  
 Weighed and transferred 42.0 mg of potassium chloride standard into 50 ml flask, added 
30 ml diluent and sonicate 5.0 mins and diluted volume with diluent. Filtered Through 0.45 
filter. 
Sample preparation:  
 Weighed 20 tablets and determine the average weight .Weigh and transferred the 
powdered tablets equivalent to 210 mg into 250 ml flask , add 150 ml diluent, sonicate 40 mins 
with intermediate shaking and kept 15 minutes for settling down and make up volume with 
diluent, mixed well. Filtered through 0.45μ filter and inject. 
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Procedure: 
 Before starting the system equilibrate the column with gradient composition at least 2 
Hours.  
Inject gradient (1 injection), Blank (1 injection), 6 Standard preparation and check for system 
suitability parameters,  
The% RSD for area response of 6 replicate injection should be not more than 5.0 %  
Tailing factor for standard peak should not be more than 2.0 
If system suitability parameters pass inject sample preparation one injection into chromatograph.  
Record the chromatograms. 
 
Note: Calculate the sum area response of potassium and chloride peaks. 
Calculate assay content in % of potassium chloride per tablet, by using the following formula. 
 
AW
LC
100
100
P
1
DT
DS
WS
AS
AT ×××××=
 
Calculate assay content in mg of potassium chloride per tablet, by using the following formula. 
 
LC
100
 tabletchloride potassium of % ×  
Where, 
AT : The sum Area of potassium and chloride peak from sample chromatogram. 
As : The sum Area of potassium and chloride peak from standard chromatogram. 
Ws : Weight of potassium chloride standard in mg. 
Ds : Dilution of standard solution. 
Dt : Dilution of sample solution. 
P : Potency of potassium chloride standard 
LC : Label claim of potassium chloride in mg per tablet.[33] 
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8. FORMULATION TRIALS: 
Table No: 8 Formula of potassium chloride Extended release tablets   
S. 
No Ingredients 
Direct 
compression Wet granulation 
F1 F2 F3 F4 F5 F6 F7 
(mg/
tab) 
(mg/
tab) 
(mg/
tab) 
(mg/
tab) 
(mg/
tab) 
(mg/
tab) 
(mg/
tab) 
1 Potassium chloride 750 750 750 750 750 750 750 
2 Hydrogenated vegetable oil 230 230 220 220 150 150 150 
3 Ethocel 100 FP -- -- -- -- 30 50 70 
4 Ethocel 10 FP -- -- -- -- 15 15 15 
5 Hydroxyl propyl cellulose -- -- 20 30 -- -- -- 
6 Isopropyl alcohol   Q.S Q.S Q.S Q.S Q.S 
7 Colloidal silicon dioxide 5 10 5 5 10 10 10 
8 Talc 5 10 5 5 5 5 5 
9 Magnesium stearate 10 10 10 10 10 10 10 
10 Core Average weight 1000 1010 1010 1020 970 990 1010
11 Opadry II yellow 854520112 -- 30 30 30 30 30 30 
12 Coated Average weight -- 1040 1040 1050 1000 1020 1040
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9. RESULTS 
9.1 Blend parameters: 
Table No: 9 Blend parameters 
S.No 
Number of 
Formulation 
LOD 
Bulk 
density 
(gms/ml) 
Tap density 
(gms/ml) 
Compressibility 
index % 
Hausner’s 
ratio 
1. F1 --- 0.781 0.937 16.59 1.198 
2. F2 --- 0.810 0.967 16.31 1.193 
3. F3 1.33% 0.751 0.882 14.96 1.176 
4. F4 1.39% 0.732 0.833 12.16 1.137 
5. F5 1.56% 0.789 0.909 13.21 1.152 
6. F6 0.45% 0.750 0.857 12.50 1.142 
7. F7 0.06% 0.831 0.909 8.58 1.093 
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9.2 SIEVE ANALYSIS 
% of granules retained 
Table No: 10  % of granules retained in gm.  
S.No 
Mesh 
size 
F1 F2 F3 F4 F5 F6 F7 
1. 20# 2.50 3.34 9.32 10.24 11.32 8.82 11.15 
2. 30# 3.96 3.76 10.62 11.98 12.94 11.55 13.45 
3. 40# 4.38 4.72 9.59 10.76 11.31 10.22 11.81 
4. 80# 36.43 34.58 48.81 43.41 49.26 50.98 48.46 
5. 100# 16.22 20.22 5.96 4.81 4.48 4.02 5.89 
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9.3 AVERAGE WEIGHT: 
Table No: 11  Average Weight in mg. 
S.No F1 F2 F3 F4 F5 F6 F7 
1. 1000.5 1010 1035 1014 968 993 1009 
2. 999.34 1009 1012 1020 975 990 1005 
3. 998 1012 1011 1016 971 986 1011 
4. 1003 1010 1005 1019 970 989 1011 
5. 1000.23 1007.2 1010 1024 965 990 1010 
6. 998.8 1013 1009 1021 968 992 1008 
7. 999.11 1010 1010 1020 972 993 1014 
8. 1000.24 1009 1008 1019 974 990 1010 
9. 1002 1008 1011 1018 966 988 1007 
10. 1001.21 1010 1006 1017 971 987 1014 
Min 998 1006 1005 1016 966 986 1005 
Max 1003 1013 1011 1024 975 993 1014 
 
 
Formulation development &in-vitro evaluation of potassium chloride extended release tablets 
Department of Pharmaceutics 73 JKKMMRF’s College Pharmacy 
9.4 THICKNESS, HARDNESS AND FRIABILTY VALUES: 
Table : 12 Post compression parameters 
 
Name of 
the tests 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
 
F7 
 
Thickness 
(mm) 
 
5.75 
 
5.78 
 
6.25 
 
6.30 
 
6.85 
 
6.58 
 
7.15 
 
Hardness 
(Newton) 
 
40N 
 
70N 
 
75N 
 
68N 
 
100N 
 
70N 
 
68N 
 
Friability 
(%) 
 
1.11% 
 
0.99% 
 
0.7% 
 
0.19% 
 
0.17% 
 
0.15% 
 
0.13% 
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9.5 COMPARATIVE DISSOLUTION PROFILE (% DRUG RELEASE) 
FORMULATION 3: 
Table No: 13 Dissolution data for F3 
Time 
intervals 
(hrs) 
Reference F3 
1 42.1 58.3 
2 53.1 63.6 
4 54.9 74.1 
6 63.5 83.8 
8 67.1 85.5 
12 80.6 85.6 
 
Figure No: 6 Dissolution profile for referfence F3  
 
F1 Value (Acceptance criteria 0-15) = 24.80 
F2 Value (Acceptance criteria 50-100) = 40.07 
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Formulation 4: 
Table No: 14 Dissolution data for F4       
Time intervals
(hrs) 
(Reference) F4 
1 42.1 54.4 
2 53.1 67.6 
4 54.9 85.7 
6 63.5 96.2 
8 67.1 102.4 
12 80.6 101.0 
 
Figure No:7 Dissolution profile for referfence F4 
 
F1 Value (Acceptance criteria 0-15) = 40.41 
F2 Value (Acceptance criteria 50-100) =30.45 
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Formulation: 5 
Table No: 15 Dissolution data for F5 
Time intervals 
(hrs) 
Reference F5 
1 42.1 49.2 
2 53.1 66.3 
4 54.9 83.8 
6 63.5 84.6 
8 67.1 86.6 
12 80.6 98.1 
 
Figure No: 8 Dissolution profile for referfence F5 
 
F1 Value (Acceptance criteria 0-15) = 29.70 
F2 Value (Acceptance criteria 50-100) = 37.53 
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Formulation 6: 
Table No: 16 Dissolution data for F6 
Time 
intervals 
(hrs) 
 Reference F6 
1 42.1 51.5 
2 53.1 60.1 
4 54.9 71.0 
6 63.5 74.9 
8 67.1 83.7 
12 80.6 87.6 
 
Figure No: 9 Dissolution profile for referfence F6
 
        
 
F1 Value (Acceptance criteria 0-15) = 18.68 
F2 Value (Acceptance criteria 50-100) = 46.77 
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Formulation: 7 
Table No: 17 Dissolution data for F7 
Time intervals 
(hrs) 
Reference F7 
1 42.1 40.7 
2 53.1 48.9 
4 54.9 53.4 
6 63.5 58.6 
8 67.1 65.9 
12 80.6 75.4 
 
        
 
Figure No: 10 Dissolution profile for referfence F7 
 
        
 
F1 Value (Acceptance criteria 0-15) = 5.09 
F2 Value (Acceptance criteria 50-100) = 76.29 
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9.6  Assay: 
Table No: 18 Assay values of formulation trials  
Formulation no: mg/tab % release 
F3 750 99.7 
F4 750 100.2 
F5 750 101 
F6 750 99.9 
F7 750 100.3 
 
9.7  STABILITY DATA   
Description:  
Round shape yellow colour tablets, debossed with “KC10” were monitored under the 
Temperature and Relative humidity (40°C ± 2°C and  75% RH ± 5%). 
 
   
Table No: 19 Stability Data  
F7 Tests  Initial  One month  
Assay  100.1 % 100 % 
Dissolution at 2 hrs.  48.9 % 49.5 % 
Water by KF  0.42 % 0.43 % 
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10. DISCUSSION 
 
F1 & F2: 
 In the present study of potassium chloride extended release tablet were formulated by 
direct compression method, in these trials the blend parameters like bulk density, tapped density, 
compressibility index and Hausner’s ratio showed poor flow property characteristics of blend. 
This was reflected in the compression as the tablets showed weight variation. During the 
compression lamination was observed at the hardness above 50N, weight variation observed, 
friability also more than the acceptance limit (1%), hence next trial is planned to perform with 
non-aqueous granulation to check the process feasibility. 
F3 
 This trial was formulated by non-aqueous granulation method using of binder 
HPC(hydroxyl propyl cellulose).The blend parameters like bulk density, tapped density, 
compressibility index and Hausner’s ratio showed passable flow property characteristics of 
blend. During the compression at above 100-110N lamination was observed, friability and 
lamination tendency was comparatively decreased than previous batch, during the film coating 
uniform distribution of film was not completely attained. Dissolution is faster than reference, 
Dissolution profile will not match with F1, F2 acceptance criteria. Hence it was suggested to 
increase the binder levels. 
F4 
The blend parameters like bulk density, tapped density, compressibility index and 
Hausner’s ratio showed good flow property, But During the granulation in RMG some extent 
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over wetting was observed, during drying large lumps are not broken, Tablets parameter like 
thickness, hardness, friability, was found to be satisfactory., friability problem was significantly 
minimized, lamination was observed during the hardness testing of the tablets at above 90N. And 
indicating dissolution profile will not match with F1, F2 acceptance criteria. Dissolution is faster 
than reference, hence further trials were planned with Ethyl cellulose to control the release. 
F5&F6 
 These trials were formulated by wet granulation method using ethyl cellulose 100cps 
30mg/tab and 50mg/tab of respectively, Physical appearance of the tablets found to be 
satisfactory in both batches, Dissolution profile will not match with F1, F2 acceptance criteria. 
But the problem was significantly minimized, hence it was suggested to increase the polymers 
level.  
F7 
This trial was formulated by wet granulation method used ethyl cellulose 100 cps in 70mg/tab, 
The blend parameters like bulk density, tapped density, compressibility index and Hausner’s 
ratio showed excellent flow property, Granules were compressed at a hardness of 65-
70Newtons.Tablets parameter like thickness, hardness and friability, was found to be 
satisfactory, indicating drug release was similar to compared with reference product. Dissolution 
profile of this trial was within the F1, F2 acceptance criteria.  
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11. CONCLUSION 
In the present study, Potassium chloride extended release tablets were prepared using non 
aqueous granulation method. Ethyl cellulose (Ethocel 100 FP) used as release controlling 
polymer, Ethyl cellulose (Ethocel 10 FP) used as a binder. Different level of Ethyl cellulose 
(Ethocel 100 FP) used in the development and F 7 experiment with Ethyl cellulose (Ethocel 100 
FP) 70mg/tab was considered to the optimum since dissolution profile is comparable with 
reference product. F7 was located for stability, up to one month duration tablets were stable in 
40°C ± 2°C  75% RH ± 5%, stability process still going on.  
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